Abstract
The skeleton is constantly being remodelled through the simultaneous resorption of bone and formation of new bone. Significant effects on bone metabolism are produced due to cancer treatment especially of breast and prostate origin, even in the absence of bone metastases. These pathological changes are known as cancer treatment-induced bone loss. Bone mass loss and osteoporosis may cause an increased risk of fractures due to a reduction in bone volume and microarchitectural deterioration. On the other hand, the skeleton is both the most common organ affected by metastatic cancer and the site that produces the greatest morbidity for patients.
Recent advances in our understanding of bone biology and the pathways by which cancer metastasizes and spreads to bone have contributed to the development of several important new drugs targeting these processes. This article summarizes our current knowledge and recommendations to advanced biology of metastasis, focusing on breast and prostate cancer.
Keywords: Aromatase inhibitors, alendronate, bisphosphonate, breast cancer, denosumab, mevalonate pathway, osteoporosis, prostate cancer, RANK, zoledronic acid.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities
Volume: 13 Issue: 2
Author(s): Ioannis Legakis and Konstantinos Syrigos
Affiliation:
Keywords: Aromatase inhibitors, alendronate, bisphosphonate, breast cancer, denosumab, mevalonate pathway, osteoporosis, prostate cancer, RANK, zoledronic acid.
Abstract: The skeleton is constantly being remodelled through the simultaneous resorption of bone and formation of new bone. Significant effects on bone metabolism are produced due to cancer treatment especially of breast and prostate origin, even in the absence of bone metastases. These pathological changes are known as cancer treatment-induced bone loss. Bone mass loss and osteoporosis may cause an increased risk of fractures due to a reduction in bone volume and microarchitectural deterioration. On the other hand, the skeleton is both the most common organ affected by metastatic cancer and the site that produces the greatest morbidity for patients.
Recent advances in our understanding of bone biology and the pathways by which cancer metastasizes and spreads to bone have contributed to the development of several important new drugs targeting these processes. This article summarizes our current knowledge and recommendations to advanced biology of metastasis, focusing on breast and prostate cancer.
Export Options
About this article
Cite this article as:
Legakis Ioannis and Syrigos Konstantinos, Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/18715303112129990027
DOI https://dx.doi.org/10.2174/18715303112129990027 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Current Pharmaceutical Design Combining Drug-Loaded Nanobubbles and Extracorporeal Shock Waves for Difficult-to-Treat Cancers
Current Drug Delivery Streamlined In Vivo Selection and Screening of Human Prostate Carcinoma Avid Phage Particles for Development of Peptide Based In Vivo Tumor Imaging Agents
Combinatorial Chemistry & High Throughput Screening Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Assessment of Signal Peptides to Optimize Interleukin 2 (IL-2) Folding and Expression
Current Proteomics High-Dose Linoleic Acid Activated JAK2-STAT3 Signaling Pathway Involved in Cytokine Production and Lipogenesis in Pancreatic Exocrine Cells
Current Molecular Medicine Opioids and Cannabinoids Interactions: Involvement in Pain Management
Current Drug Targets Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
Current Medicinal Chemistry - Anti-Cancer Agents Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Current Cancer Drug Targets Stem Cell-Mediated Gene Delivering for the Treatment of Cerebral Ischemia: Progress and Prospectives
Current Drug Targets Telomeres, Telomerase and Malignant Transformation
Current Molecular Medicine Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design The Therapeutic Potential of Small Activating RNAs for Colorectal Carcinoma
Current Gene Therapy Resveratrol and Prostate Cancer: The Power of Phytochemicals
Current Medicinal Chemistry 6-Chloro-7-methyl-3', 4'-dimethoxyflavone – a Potent Selective COX-2 Inhibitor
Medicinal Chemistry